Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
592 Results for "
PD1
" in MedChemExpress (MCE) Product Catalog:
Products (592)
592 Results for "PD1" in MCE Product Catalog:
39
39 Publications Verification
Target:
Áreas de investigación:
MSA-2, a potent and orally available non-nucleotide STING agonist, is bound to STING as a noncovalent dimer with nanomolar affinity. MSA-2 shows EC50s of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. MSA-2 stimulates interferon-β secretion in tumors, induces tumor regression with durable antitumor immunity, and synergizes with anti-PD-1 in syngeneic mouse tumor models [1] .
37
37 Cited Publications
Referencia número: HY-P9902A
Synonyms: MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)
Target:
Áreas de investigación:
37
37 Cited Publications
Referencia número: HY-P9902
No. CAS: 1374853-91-4
Synonyms: MK-3475; Lambrolizumab
Target:
Áreas de investigación:
36
36 Cited Publications
Referencia número: HY-19991
No. CAS: 1675201-83-8
Synonyms: PD-1/PD-L1 inhibitor 1
Target:
Áreas de investigación:
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) [1] .
34
34 Cited Publications
Referencia número: HY-P99144
Target:
Áreas de investigación:
29
29 Cited Publications
Referencia número: HY-19745
No. CAS: 1675203-84-5
Target:
Áreas de investigación:
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity [1] .
29
29 Cited Publications
Referencia número: HY-19745B
No. CAS: 2089334-95-0
Target:
Áreas de investigación:
BMS-202 hydrochloride is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 hydrochloride binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 hydrochloride has antitumor activity [1] .
25
25 Cited Publications
Referencia número: HY-P9903
No. CAS: 946414-94-4
Synonyms: BMS-936558; ONO-4538; MDX-1106
Target:
21
21 Cited Publications
Referencia número: HY-P99145
Target:
Áreas de investigación:
12
12 Cited Publications
Target:
Áreas de investigación:
Ro 25-6981 is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 has the potential for the research of parkinson's disease (PD) .
12
12 Cited Publications
Target:
Áreas de investigación:
Ro 25-6981 Maleate is a potent, selective and activity-dependent NR2B subunit specific NMDA receptor antagonist. Ro 25-6981 Maleat shows anticonvulsant and anti-parkinsonian activity. Ro 25-6981 Maleate has the potential for the research of parkinson's disease (PD) .
7
Target:
Áreas de investigación:
Durvalumab (MEDI-4736) is an human anti-PD-L1 monoclonal antibody [1]. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
7
7 Cited Publications
Referencia número: HY-P9919A
No. CAS: 1428935-60-7
Synonyms: MEDI 4736 (anti-PD-L1)
Target:
Áreas de investigación:
Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity [1] .
7
7 Cited Publications
Referencia número: HY-P990679
Target:
Áreas de investigación:
6
6 Cited Publications
Target:
Áreas de investigación:
BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation [1] .
6
6 Cited Publications
Target:
Áreas de investigación:
BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation [1] .
6
Áreas de investigación:
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively [1]. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
5
5 Cited Publications
Referencia número: HY-P9971
No. CAS: 1798286-48-2
Synonyms: SHR-1210; INCSHR1210
Target:
Áreas de investigación:
4
4 Cited Publications
Target:
Áreas de investigación:
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model [1].
4
4 Cited Publications
Referencia número: HY-132192A
Pureza: 99.26%
Target:
Áreas de investigación:
PD-1/PD-L1-IN-9 hydrochloride is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 hydrochloride can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 hydrochloride also exhibits significant in vivo antitumor activity in a CT26 mouse model [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
